Moderna (MRNA) Change in Cash (2018 - 2026)

Moderna (MRNA) has reported Change in Cash for 9 consecutive years, with -$185.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Change in Cash rose 46.38% year-over-year to -$185.0 million in Q2 2026; TTM through Jun 2026 was $443.0 million, a 136.95% increase from a year earlier, with the FY2025 full-year figure at $668.0 million, up 166.87% from the prior year.
• Change in Cash was -$185.0 million for Q2 2026 at Moderna, up from -$688.0 million in the prior quarter.
• Over five years, Change in Cash peaked at $1.5 billion in Q4 2025 and troughed at -$2.2 billion in Q2 2022.
• A 5-year average of -$285.3 million and a median of -$166.0 million in 2025 frame the typical range for Change in Cash.
• Across the five-year window, Change in Cash tumbled 1450.93% in 2022 and jumped 1228.0% in 2024, its largest moves.
• Over 5 years, Change in Cash stood at $176.0 million in 2022, then slumped by 114.2% to -$25.0 million in 2023, then jumped by 1228.0% to $282.0 million in 2024, then soared by 418.79% to $1.5 billion in 2025, then tumbled by 112.65% to -$185.0 million in 2026.
• The last three Change in Cash figures came in at -$185.0 million (Q2 2026), -$688.0 million (Q1 2026), and $1.5 billion (Q4 2025), per Business Quant data.